GlassScriptPhysician profile
Thomas Fordham Wilson
NPI 1730503657
$18,384.53
in general payments reported to CMS, 2019-2025
29 companies · $3,522 in 2025
The $3,522 reported for 2025 was more than what 78% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $1,673 · 2021: $2,534 · 2022: $6,596 · 2023: $2,477 · 2024: $1,002 · 2025: $3,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,274 · Travel and Lodging: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,274.19 |
| Travel and Lodging | $2,726.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,950.50 | 2021-2025 | Diamondback Coronary, Supera, Optis |
| Boston Scientific Corporation | $4,209.50 | 2020-2025 | Avvigo Guidance System, Rotablator Rotational Atherectomy System Console Kit, Opticross |
| Medtronic, INC. | $2,140.47 | 2021-2025 | Micra, Turbohawk, Mvp |
| Edwards Lifesciences Corporation | $1,571.68 | 2021-2022 | |
| Abiomed | $1,103.56 | 2022-2025 | Impella |
| Cardiovascular Systems INC. | $635.32 | 2019-2023 | Diamondback Coronary |
| Janssen Pharmaceuticals, INC | $458.09 | 2020-2024 | Xarelto |
| Shockwave Medical, INC | $447.64 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $391.42 | 2019-2020 | |
| Banner Surgical Solutions, INC | $351.97 | 2025 | |
| Acist Medical Systems, INC. | $312.14 | 2020-2024 | |
| Asahi Intecc USA, INC. | $273.20 | 2022-2024 | Peripheral Vascular |
| Stryker Corporation | $255.72 | 2025 | Clottriever Bold Catheter, Flowtriever |
| Astellas Pharma US INC | $211.32 | 2019-2022 | |
| Philips North America LLC | $185.96 | 2021-2024 | (Bk5) Azurion 5 M20 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $128.13 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $118.12 | 2022-2024 | Wainua, Farxiga |
| Actelion Pharmaceuticals US, INC. | $112.26 | 2022-2023 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $94.72 | 2021-2024 | |
| Inspire Medical Systems, INC. | $85.64 | 2024 | Inspire |
| Amgen INC. | $77.17 | 2023-2024 | Repatha |
| Akcea Therapeutics, INC. | $59.45 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.20 | 2019 | |
| Angiodynamics, INC. | $40.08 | 2025 | Auryon Laser System 100-120 Vac |
| Regeneron Healthcare Solutions, INC. | $37.08 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $28.42 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.70 | 2022 | |
| Orthofix Medical, INC. | $17.17 | 2025 | Cervical-Stim |
| Amarin Pharma, INC. | $16.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.